MBX Biosciences (NASDAQ:MBX) Price Target Raised to $86.00 at Citizens Jmp

MBX Biosciences (NASDAQ:MBX) had its price target boosted by investment analysts at Citizens Jmp from $76.00 to $86.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s target price would indicate a potential upside of 114.57% from the stock’s current price.

Other equities analysts have also issued reports about the stock. TD Cowen restated a “buy” rating on shares of MBX Biosciences in a research report on Thursday, March 12th. Lifesci Capital raised shares of MBX Biosciences to a “strong-buy” rating in a research note on Tuesday, March 31st. Wall Street Zen raised shares of MBX Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday. Citigroup reissued an “outperform” rating on shares of MBX Biosciences in a research note on Tuesday. Finally, Barclays reaffirmed an “overweight” rating on shares of MBX Biosciences in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, MBX Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $59.11.

MBX Biosciences Stock Performance

MBX opened at $40.08 on Tuesday. MBX Biosciences has a fifty-two week low of $9.43 and a fifty-two week high of $45.85. The company has a fifty day moving average of $31.18 and a two-hundred day moving average of $31.40. The stock has a market capitalization of $1.91 billion, a price-to-earnings ratio of -18.14 and a beta of 0.78.

MBX Biosciences (NASDAQ:MBX) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.15. On average, equities research analysts forecast that MBX Biosciences will post -2.9 earnings per share for the current year.

Insider Activity

In other MBX Biosciences news, CEO P. Kent Hawryluk bought 18,500 shares of the company’s stock in a transaction on Friday, March 13th. The stock was purchased at an average cost of $28.41 per share, for a total transaction of $525,585.00. Following the acquisition, the chief executive officer owned 486,777 shares of the company’s stock, valued at $13,829,334.57. The trade was a 3.95% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

Institutional Investors Weigh In On MBX Biosciences

Several hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. increased its stake in shares of MBX Biosciences by 4,131.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company’s stock valued at $26,000 after acquiring an additional 1,446 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in MBX Biosciences during the third quarter valued at approximately $27,000. GF Fund Management CO. LTD. acquired a new position in shares of MBX Biosciences during the fourth quarter worth $28,000. Strs Ohio lifted its position in shares of MBX Biosciences by 128.6% during the first quarter. Strs Ohio now owns 1,600 shares of the company’s stock worth $48,000 after purchasing an additional 900 shares in the last quarter. Finally, Royal Bank of Canada lifted its position in shares of MBX Biosciences by 59.6% during the fourth quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock worth $49,000 after purchasing an additional 572 shares in the last quarter.

More MBX Biosciences News

Here are the key news stories impacting MBX Biosciences this week:

• Positive Sentiment: Truist Financial raised its price target on MBX Biosciences to $70 from $50 and kept a buy rating, signaling stronger upside expectations for the stock. Benzinga
• Positive Sentiment: MBX Biosciences released initial Phase 1 data for MBX 4291 showing mean weight loss of 7% at 8 weeks and supporting the potential for once-monthly dosing, a positive sign for its obesity pipeline. GlobeNewswire
• Neutral Sentiment: Lifesci Capital reiterated a Strong-Buy view while modestly adjusting several earnings estimates for MBX, including a lower Q3 and Q4 outlook but a slightly better Q2 estimate. The revisions suggest analysts still like the story, even though near-term losses remain expected. MarketBeat
• Neutral Sentiment: The company also drew added investor attention from a Seeking Alpha transcript discussing its obesity therapeutics portfolio and clinical progress, but this appears more informational than directly market-moving. Seeking Alpha
• Negative Sentiment: Lifesci Capital trimmed its Q3 2026 and Q4 2026 EPS estimates, which may weigh on sentiment because it points to weaker expected profitability in the near term. MarketBeat
• Negative Sentiment: The firm also lowered its FY2026 earnings estimate slightly versus prior modeling, underscoring that MBX is still expected to post significant losses as it advances its pipeline. MarketBeat

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.